Delayed
Japan Exchange
09:21:39 2024-07-16 pm EDT
|
5-day change
|
1st Jan Change
|
3,482
JPY
|
-0.20%
|
|
+0.90%
|
-30.28%
|
Fiscal Period: March |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
2027
|
---|
Capitalization
1 |
571,160
|
554,319
|
561,052
|
392,668
|
301,067
|
234,994
|
-
|
-
|
Enterprise Value (EV)
1 |
524,046
|
493,520
|
503,199
|
323,731
|
235,236
|
163,135
|
148,318
|
134,949
|
P/E ratio
|
33.9
x
|
26.8
x
|
22.5
x
|
17.2
x
|
11.6
x
|
9.24
x
|
8.63
x
|
9.16
x
|
Yield
|
1.01%
|
1.2%
|
1.32%
|
1.96%
|
2.77%
|
3.63%
|
3.71%
|
3.73%
|
Capitalization / Revenue
|
4.9
x
|
4.55
x
|
4.08
x
|
2.72
x
|
2.03
x
|
1.54
x
|
1.47
x
|
1.45
x
|
EV / Revenue
|
4.49
x
|
4.05
x
|
3.66
x
|
2.25
x
|
1.59
x
|
1.07
x
|
0.93
x
|
0.83
x
|
EV / EBITDA
|
20.8
x
|
16.6
x
|
16.1
x
|
9.23
x
|
6.14
x
|
4.28
x
|
3.63
x
|
3.45
x
|
EV / FCF
|
51.2
x
|
26.2
x
|
52.1
x
|
37.9
x
|
36.9
x
|
7.53
x
|
6.6
x
|
7.49
x
|
FCF Yield
|
1.95%
|
3.81%
|
1.92%
|
2.64%
|
2.71%
|
13.3%
|
15.2%
|
13.4%
|
Price to Book
|
3.93
x
|
3.42
x
|
3.11
x
|
2.01
x
|
1.37
x
|
0.99
x
|
0.92
x
|
0.87
x
|
Nbr of stocks (in thousands)
|
67,354
|
67,353
|
67,353
|
67,353
|
67,353
|
67,353
|
-
|
-
|
Reference price
2 |
8,480
|
8,230
|
8,330
|
5,830
|
4,470
|
3,489
|
3,489
|
3,489
|
Announcement Date
|
5/13/20
|
5/14/21
|
5/11/22
|
5/11/23
|
5/10/24
|
-
|
-
|
-
|
Fiscal Period: March |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
2027
|
---|
Net sales
1 |
116,637
|
121,885
|
137,484
|
144,175
|
148,255
|
152,243
|
159,480
|
162,591
|
EBITDA
1 |
25,136
|
29,684
|
31,232
|
35,090
|
38,318
|
38,104
|
40,809
|
39,158
|
EBIT
1 |
21,668
|
26,134
|
32,948
|
30,049
|
33,295
|
32,550
|
35,159
|
33,087
|
Operating Margin
|
18.58%
|
21.44%
|
23.96%
|
20.84%
|
22.46%
|
21.38%
|
22.05%
|
20.35%
|
Earnings before Tax (EBT)
1 |
22,442
|
28,759
|
33,301
|
30,489
|
33,616
|
32,950
|
35,538
|
33,466
|
Net income
1 |
16,866
|
20,702
|
24,986
|
22,812
|
25,851
|
25,626
|
27,218
|
25,652
|
Net margin
|
14.46%
|
16.98%
|
18.17%
|
15.82%
|
17.44%
|
16.83%
|
17.07%
|
15.78%
|
EPS
2 |
250.4
|
307.4
|
371.0
|
338.7
|
383.8
|
377.6
|
404.1
|
380.8
|
Free Cash Flow
1 |
10,237
|
18,805
|
9,659
|
8,539
|
6,368
|
21,658
|
22,483
|
18,022
|
FCF margin
|
8.78%
|
15.43%
|
7.03%
|
5.92%
|
4.3%
|
14.23%
|
14.1%
|
11.08%
|
FCF Conversion (EBITDA)
|
40.73%
|
63.35%
|
30.93%
|
24.33%
|
16.62%
|
56.84%
|
55.09%
|
46.02%
|
FCF Conversion (Net income)
|
60.7%
|
90.84%
|
38.66%
|
37.43%
|
24.63%
|
84.51%
|
82.6%
|
70.25%
|
Dividend per Share
2 |
86.00
|
99.00
|
110.0
|
114.0
|
124.0
|
126.6
|
129.4
|
130.1
|
Announcement Date
|
5/13/20
|
5/14/21
|
5/11/22
|
5/11/23
|
5/10/24
|
-
|
-
|
-
|
Fiscal Period: March |
2020 S2
|
2021 S1
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 S1
|
2025 Q3
|
2025 Q4
|
2026 Q1
|
2026 S1
|
---|
Net sales
1 |
59,250
|
57,817
|
71,568
|
34,650
|
31,329
|
35,619
|
71,136
|
38,783
|
34,256
|
37,012
|
36,302
|
73,314
|
39,414
|
35,527
|
37,423
|
37,150
|
74,500
|
39,000
|
37,715
|
39,700
|
80,000
|
EBITDA
1 |
-
|
-
|
-
|
8,568
|
-293
|
-
|
-
|
10,117
|
3,424
|
-
|
-
|
-
|
10,805
|
4,173
|
8,715
|
6,785
|
-
|
11,300
|
9,100
|
-
|
-
|
EBIT
1 |
10,643
|
11,140
|
21,504
|
7,817
|
-1,022
|
10,276
|
19,161
|
8,826
|
2,062
|
11,163
|
9,715
|
20,878
|
9,572
|
2,845
|
7,962
|
7,342
|
14,000
|
9,550
|
6,465
|
8,700
|
17,000
|
Operating Margin
|
17.96%
|
19.27%
|
30.05%
|
22.56%
|
-3.26%
|
28.85%
|
26.94%
|
22.76%
|
6.02%
|
30.16%
|
26.76%
|
28.48%
|
24.29%
|
8.01%
|
21.27%
|
19.76%
|
18.79%
|
24.49%
|
17.14%
|
21.91%
|
21.25%
|
Earnings before Tax (EBT)
1 |
11,171
|
11,248
|
22,250
|
8,313
|
-790
|
10,514
|
19,398
|
9,024
|
2,067
|
11,440
|
9,706
|
21,146
|
9,827
|
2,643
|
8,105
|
7,472
|
14,200
|
9,710
|
6,585
|
8,900
|
17,200
|
Net income
1 |
8,575
|
8,073
|
16,561
|
6,045
|
438
|
8,249
|
15,222
|
7,452
|
138
|
8,749
|
-
|
16,176
|
7,826
|
1,849
|
6,205
|
5,722
|
10,900
|
7,460
|
5,535
|
5,300
|
12,800
|
Net margin
|
14.47%
|
13.96%
|
23.14%
|
17.45%
|
1.4%
|
23.16%
|
21.4%
|
19.21%
|
0.4%
|
23.64%
|
-
|
22.06%
|
19.86%
|
5.2%
|
16.58%
|
15.4%
|
14.63%
|
19.13%
|
14.68%
|
13.35%
|
16%
|
EPS
2 |
-
|
119.9
|
245.9
|
89.75
|
6.500
|
122.5
|
226.0
|
110.6
|
2.050
|
129.9
|
-
|
240.2
|
116.2
|
27.45
|
91.96
|
96.80
|
161.8
|
96.80
|
66.37
|
78.70
|
190.0
|
Dividend per Share
2 |
-
|
49.00
|
51.00
|
-
|
-
|
-
|
57.00
|
-
|
-
|
-
|
62.00
|
62.00
|
-
|
62.00
|
-
|
65.00
|
-
|
-
|
65.00
|
-
|
-
|
Announcement Date
|
5/13/20
|
11/5/20
|
11/10/21
|
2/10/22
|
5/11/22
|
8/9/22
|
11/10/22
|
2/10/23
|
5/11/23
|
8/10/23
|
11/13/23
|
11/13/23
|
2/9/24
|
5/10/24
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: March |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
2027
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
47,114
|
60,799
|
57,853
|
68,937
|
65,831
|
71,859
|
86,676
|
100,044
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
10,237
|
18,805
|
9,659
|
8,539
|
6,368
|
21,658
|
22,483
|
18,022
|
ROE (net income / shareholders' equity)
|
12%
|
13.5%
|
13.6%
|
12.1%
|
12.4%
|
11.2%
|
11.3%
|
9.94%
|
ROA (Net income/ Total Assets)
|
13.1%
|
14.4%
|
16%
|
9.97%
|
10.3%
|
10.3%
|
9.95%
|
9.01%
|
Assets
1 |
129,182
|
143,910
|
156,428
|
228,696
|
250,429
|
248,050
|
273,555
|
284,562
|
Book Value Per Share
2 |
2,160
|
2,409
|
2,681
|
2,904
|
3,270
|
3,528
|
3,793
|
4,018
|
Cash Flow per Share
2 |
302.0
|
360.0
|
439.0
|
414.0
|
458.0
|
474.0
|
474.0
|
423.0
|
Capex
1 |
2,500
|
2,583
|
10,744
|
5,660
|
16,430
|
7,325
|
7,888
|
7,550
|
Capex / Sales
|
2.14%
|
2.12%
|
7.81%
|
3.93%
|
11.08%
|
4.81%
|
4.95%
|
4.64%
|
Announcement Date
|
5/13/20
|
5/14/21
|
5/11/22
|
5/11/23
|
5/10/24
|
-
|
-
|
-
|
Last Close Price
3,489
JPY Average target price
3,987
JPY Spread / Average Target +14.28% Consensus |
1st Jan change
|
Capi.
|
---|
| -30.28% | 1.52B | | +61.53% | 856B | | +38.95% | 631B | | -3.66% | 359B | | +15.06% | 325B | | +9.18% | 297B | | +5.89% | 234B | | +16.53% | 226B | | +15.67% | 177B | | +2.47% | 165B |
Other Pharmaceuticals
|